Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance
N/A
N/A
Male
Prostate Cancer
Trial Information
Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance
1. To perform a large scale assessment of tissue hypoxia by pimonidazole and hypoxia
marker gene expression in human prostate cancers
2. To characterize expression and hypoxia/HIF-responsiveness of myoglobin, cytoglobin,
α-hemoglobin in prostate tumors and cell lines
3. To identify uni- and multivariate associations between marker gene expression and
clinico-pathological parameters for the detection of robust and novel prognostic tools
in prostate cancers
Inclusion Criteria
Inclusion criteria:
- Patients with biopsy-proven adenocarcinoma of the prostate who are to be treated with
radical prostatectomy at the Department of Urology, University Hospital of Zurich
- Written informed consent
Exclusion criteria:
- Metastatic prostate cancer
- Contraindications to the class of investigational product under study, e.g. known
hypersensitivity or allergy to the investigational product
- Severe heart or lung disease
- Severe liver or kidney dysfunction
- Severe stridor
- Distant metastases
- Concurrent treatment for other malignant disease
- Prior hormonal therapy or radiotherapy
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
01 Studienregister MasterAdmins
Investigator Role:
Study Director
Investigator Affiliation:
UniversitaetsSpital Zuerich
Authority:
Switzerland: Swissmedic
Study ID:
xxx
NCT ID:
NCT01191099
Start Date:
August 2010
Completion Date:
August 2020
Related Keywords:
- Prostate Cancer
- Prostatic Neoplasms
- Anoxia
Name | Location |
|---|
